OPKO Health (NASDAQ:OPK) Shares Gap Down to $1.23

Shares of OPKO Health, Inc. (NASDAQ:OPK) gapped down prior to trading on Friday . The stock had previously closed at $1.23, but opened at $1.20. OPKO Health shares last traded at $1.24, with a volume of 321,622 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on OPK shares. Piper Sandler reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of OPKO Health in a research note on Monday, April 1st. Barrington Research reaffirmed an “outperform” rating and issued a $1.50 price objective on shares of OPKO Health in a research note on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, April 3rd. Finally, StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st.

OPKO Health Trading Up 0.4 %

The business’s 50-day moving average price is $1.07 and its two-hundred day moving average price is $1.24. The company has a current ratio of 1.55, a quick ratio of 1.22 and a debt-to-equity ratio of 0.15.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). The company had revenue of $181.90 million for the quarter, compared to analysts’ expectations of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) earnings per share. As a group, equities analysts anticipate that OPKO Health, Inc. will post -0.33 earnings per share for the current fiscal year.

Insider Transactions at OPKO Health

In related news, Director Richard M. Krasno acquired 30,000 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were acquired at an average cost of $0.99 per share, with a total value of $29,700.00. Following the transaction, the director now owns 103,333 shares of the company’s stock, valued at approximately $102,299.67. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Phillip Md Et Al Frost acquired 1,500,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were acquired at an average cost of $0.98 per share, with a total value of $1,470,000.00. Following the transaction, the chief executive officer now owns 207,368,225 shares of the company’s stock, valued at approximately $203,220,860.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard M. Krasno purchased 30,000 shares of the stock in a transaction on Monday, January 29th. The stock was acquired at an average price of $0.99 per share, for a total transaction of $29,700.00. Following the completion of the purchase, the director now directly owns 103,333 shares in the company, valued at approximately $102,299.67. The disclosure for this purchase can be found here. Insiders have bought a total of 4,630,000 shares of company stock valued at $4,422,700 over the last three months. 47.26% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. IPG Investment Advisors LLC acquired a new position in OPKO Health in the 4th quarter valued at about $30,000. Verition Fund Management LLC acquired a new position in shares of OPKO Health during the 2nd quarter worth approximately $36,000. River Wealth Advisors LLC acquired a new position in shares of OPKO Health during the 3rd quarter worth approximately $38,000. Guggenheim Capital LLC acquired a new position in shares of OPKO Health during the 1st quarter worth approximately $38,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of OPKO Health during the 1st quarter worth approximately $39,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.